Prodrug Strategies in Ocular Drug Delivery

被引：41

作者：

Barot, Megha ^{[1
]}

Bagui, Mahuya ^{[1
]}

Gokulgandhi, Mitan R. ^{[1
]}

Mitra, Ashim K. ^{[1
]}

机构：

[1] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA

来源：

MEDICINAL CHEMISTRY | 2012年 / 8卷 / 04期

关键词：

Prodrug; transporter; receptor; drug delivery; BLOOD-RETINAL BARRIER; AMINO-ACID TRANSPORTER; IN-VITRO EVALUATION; CORNEAL EPITHELIAL-CELLS; PIGMENTED RABBIT CONJUNCTIVA; CARBONIC-ANHYDRASE INHIBITORS; GLYCOPROTEIN-MEDIATED EFFLUX; DIPEPTIDE ESTER PRODRUGS; WATER-SOLUBLE PRODRUGS; FOLATE RECEPTOR-ALPHA;

D O I：

10.2174/157340612801216283

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Poor bioavailability of topically instilled drug is the major concern in the field of ocular drug delivery. Efflux transporters, static and dynamic ocular barriers often possess rate limiting factors for ocular drug therapy. Different formulation strategies like suspension, ointment, gels, nanoparticles, implants, dendrimers and liposomes have been employed in order to improve drug permeation and retention by evading rate limiting factors at the site of absorption. Chemical modification such as prodrug targeting various nutrient transporters (amino acids, peptide and vitamin) has evolved a great deal of interest to improve ocular drug delivery. In this review, we have discussed various prodrug strategies which have been widely applied for enhancing therapeutic efficacy of ophthalmic drugs. The purpose of this review is to provide an update on the utilization of prodrug concept in ocular drug delivery. In addition, this review will highlight ongoing academic and industrial research and development in terms of ocular prodrug design and delivery.

引用

页码：753 / 768

页数：16

共 196 条

[11] Carrier mediated uptake of L-tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC) - strategy for the design of transporter/receptor targeted prodrugs [J].

Balakrishnan, A ;

Jain-Vakkalagadda, B ;

Yang, C ;

Pal, D ;

Mitra, AK .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 247 (1-2) :115-125

[12]

Ban Y, 2000, DEV BRAIN RES, V121, P89

[13] Effect of Emergence of Fluoroquinolone Resistance on Intrinsic Expression of P-Glycoprotein Phenotype in Corneal Epithelial Cells [J].

Barot, Megha ;

Gokulgandhi, Mitan R. ;

Haghnegahdar, Megan ;

Dalvi, Pranjali ;

Mitra, Ashim K. .

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 27 (06) :553-559

[14] Mitochondrial Dysfunction in Retinal Diseases [J].

Barot, Megha ;

Gokulgandhi, Mitan R. ;

Mitra, Ashim K. .

CURRENT EYE RESEARCH, 2011, 36 (12) :1069-1077

[15]

Basu SK, 1998, INVEST OPHTH VIS SCI, V39, P2365

[16]

BAUDOUIN C, 1992, INVEST OPHTH VIS SCI, V33, P2822

[17] Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro [J].

Beadle, JR ;

Hartline, C ;

Aldern, KA ;

Rodriguez, N ;

Harden, E ;

Kern, ER ;

Hostetler, KY .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2381-2386

[18] Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection [J].

Bidanset, DJ ;

Beadle, JR ;

Wan, WB ;

Hostetler, KY ;

Kern, ER .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (03) :499-503

[19] IMPROVED DELIVERY THROUGH BIOLOGICAL-MEMBRANES .56. PHARMACOLOGICAL EVALUATION OF ALPRENOXIME - A NEW POTENTIAL ANTIGLAUCOMA AGENT [J].

BODOR, N ;

ELKOUSSI, A .

PHARMACEUTICAL RESEARCH, 1991, 8 (11) :1389-1395

[20] Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems [J].

Bodor, N ;

Buchwald, P .

AAPS JOURNAL, 2005, 7 (04) :E820-E833

← 1 2 3 4 5 6 7 8 9 10 →